

# Medicover

## Execution remains solid

- Operational leverage supports beat on adj. EBITDA
- Adj. EBITDA revised by +1-0% for '25e-'27e
- Unchanged outlook and fair value range of SEK 220-300

## Continues to show strength

Q3 proved marginally weaker than expected on sales, but operational leverage continued to improve, resulting in a 5%/3% beat on adj. EBITDA vs. ABGSCe/Infront consensus. Sales were EUR 592m (-2% vs. ABGSCe, -2% vs. cons.) with organic sales growth of +12% (ABGSCe +15%).

Within HS, growth remained solid, supported by the sport/wellness and ambulatory clinics driving FFS growth in Poland. In India, the company is reducing its exposure to public funding, which weighs on growth near term but is expected to be beneficial longer term. In DS, efficiency programmes, volume growth, and price increases continued to support margin expansion, and management highlighted that the segment has navigated the German reimbursement reform well. Both segments contributed to an overall profitability improvement, with the group adj. EBITDA margin at 17.2% (ABGSCe 16.2%, cons. 16.4%).

## Estimate changes

Overall, we leave our operational assumptions largely intact, revising adj. EBITDA by +1-0% for '25e-'27e. Management highlighted three near-term factors that will temporarily affect margins: 1) the launch of two new hospitals in India, brought forward into Q4 to capture strong momentum, 2) some early indications of a more cautious consumer, and 3) a strike in one Indian state during Q4. Despite these short-term effects, we see no changes to the company's fundamental outlook, and the long-term growth and margin expansion trajectory remains intact.

## Fair value range unchanged at SEK 220-300

With an unchanged long-term outlook and minor estimate revisions, we leave our fair value range at SEK 220-300. The range is derived from trading multiples of two peer groups, one of healthcare providers in developing markets and one in developed markets, alongside a DCF. It corresponds to a '25e EV/EBITDA of 12x-15x.

**Analyst(s):** philip.ekengren@abgsc.se, +46 8 566 294 98  
 sten.gustafsson@abgsc.se, +46 8 566 286 25

EURm	2023	2024	2025e	2026e	2027e
Sales	1,746	2,092	2,392	2,738	3,135
EBITDA	244	285	373	438	511
EBITDA margin (%)	14.0	13.6	15.6	16.0	16.3
EBIT adj.	61	70	157	200	248
EBIT adj. margin (%)	3.5	3.4	6.5	7.3	7.9
Pretax profit	24	20	96	138	186
EPS	0.12	0.11	0.48	0.67	0.90
EPS adj.	0.12	0.11	0.48	0.67	0.90
Sales growth (%)	15.6	19.8	14.4	14.5	14.5
EPS growth (%)	44.8	-5.4	nm	39.9	34.2

Source: ABG Sundal Collier, Company Data

Reason: Post-results comment

## Commissioned research

Not rated

## Healthcare

Estimate changes (%)

	2025e	2026e	2027e
Sales	-0.9	-1.1	-1.4
EBIT	0.9	-0.2	0.2
EPS	2.3	-0.3	0.3

Source: ABG Sundal Collier

## MCOV.B-SE/MCOVB SS

Share price (SEK)	4/11/2025	238.00
Fair value range		220.0-300.0

MCap (SEKm)	36,763
MCap (EURm)	3,348
No. of shares (m)	74.4
Free float (%)	87.7
Av. daily volume (k)	37

## Next event

Q4 Report 10 February 2026

## Performance



	2025e	2026e	2027e
P/E (x)	45.3	32.4	24.1
P/E adj. (x)	45.3	32.4	24.1
P/BVPS (x)	6.30	5.51	4.71
EV/EBITDA (x)	12.5	10.5	8.9
EV/EBIT adj. (x)	29.7	23.1	18.4
EV/sales (x)	1.94	1.69	1.45
ROE adj. (%)	17.9	23.5	25.7
Dividend yield (%)	0.8	1.1	1.3
FCF yield (%)	-0.1	5.4	6.4
Le. adj. FCF yld. (%)	-2.7	2.8	3.8
Net IB debt/EBITDA (x)	3.6	3.0	2.4
Le. adj. ND/EBITDA (x)	2.9	2.1	1.5

Disclosures and analyst certifications are located on pages 12-13 of this report.

This research product is commissioned and paid for by the company covered in this report. As such, this report is deemed to constitute an acceptable minor non-monetary benefit (i.e. not investment research) as defined in MiFID II.

## Company description


Medicover is an international provider of healthcare and diagnostic services. Medicover's business is divided into two segments: Healthcare Services (68% of 2023 sales) and Diagnostic Services (32%). The company focuses on providing a wide range of high-quality healthcare solutions, from hospital care and specialist services to diagnostic testing and fitness centres. Key markets include Poland (48% of sales), Germany (18%), Romania (12%) and India (11%).

### Sustainability information

## Risks


Key risks include competition from local players, executing M&A transactions and integrating acquired businesses. Regulatory changes, particularly in healthcare reimbursement policies, pose additional challenges. Other risks include the operational scale-up of certain tests and dependence on skilled healthcare professionals in competitive labour markets.

### Sales and organic growth (EURm)




Source: ABG Sundal Collier, Company data

### Annual number of members and lab tests




Source: ABG Sundal Collier, Company data

### Adj. EBITDAaL and adj. EBITDAaL margin (EURm)




Source: ABG Sundal Collier, Company data

### FCF (post M&A) and cash conversion EURm




Source: ABG Sundal Collier, Company data

### ROCE and ROIC



Source: ABG Sundal Collier, Company data

### Net debt and leverage (EURm)



Source: ABG Sundal Collier, Company data

## Estimate changes

EURm	Old	2025e New	% change	Old	2026e New	% change	Old	2027e New	% change
<b>Net sales</b>	<b>2,413.1</b>	<b>2,392.2</b>	<b>-0.9%</b>	<b>2,769.1</b>	<b>2,737.9</b>	<b>-1.1%</b>	<b>3,179.8</b>	<b>3,135.3</b>	<b>-1.4%</b>
Growth y-o-y	15.4%	14.4%	-1.0pp.	14.8%	14.5%	-0.3pp.	14.8%	14.5%	-0.3pp.
Organic growth	14.4%	13.4%	-1.1pp.	14.8%	14.5%	-0.3pp.	14.8%	14.5%	-0.3pp.
<b>EBITDA</b>	<b>370.7</b>	<b>372.7</b>	<b>0.6%</b>	<b>438.7</b>	<b>438.3</b>	<b>-0.1%</b>	<b>510.0</b>	<b>510.5</b>	<b>0.1%</b>
EBITDA margin	15.4%	15.6%	0.2pp.	15.8%	16.0%	0.2pp.	16.0%	16.3%	0.2pp.
<b>EBITDAaL</b>	<b>246.1</b>	<b>246.4</b>	<b>0.1%</b>	<b>300.3</b>	<b>299.9</b>	<b>-0.1%</b>	<b>353.6</b>	<b>354.1</b>	<b>0.1%</b>
EBITDAaL margin	10.2%	10.3%	0.1pp.	10.8%	11.0%	0.1pp.	11.1%	11.3%	0.2pp.
NRI	-14.8	-15.6	5.4%	-12.0	-12.0	0.0%	-12.0	-12.0	0.0%
<b>Adj. EBITDA</b>	<b>385.5</b>	<b>388.3</b>	<b>0.7%</b>	<b>450.7</b>	<b>450.3</b>	<b>-0.1%</b>	<b>522.0</b>	<b>522.5</b>	<b>0.1%</b>
Adj. EBITDA margin	16.0%	16.2%	0.3pp.	16.3%	16.4%	0.2pp.	16.4%	16.7%	0.2pp.
<b>Adj. EBITDAaL</b>	<b>260.9</b>	<b>262.0</b>	<b>0.4%</b>	<b>312.3</b>	<b>311.9</b>	<b>-0.1%</b>	<b>365.6</b>	<b>366.1</b>	<b>0.1%</b>
Adj. EBITDAaL margin	10.8%	11.0%	0.1pp.	11.3%	11.4%	0.1pp.	11.5%	11.7%	0.2pp.
<b>EBIT</b>	<b>155.3</b>	<b>156.6</b>	<b>0.9%</b>	<b>200.7</b>	<b>200.3</b>	<b>-0.2%</b>	<b>247.0</b>	<b>247.5</b>	<b>0.2%</b>
EBIT margin	6.4%	6.5%	0.1pp.	7.2%	7.3%	0.1pp.	7.8%	7.9%	0.1pp.
Pre tax profit	94.7	96.0	1.4%	138.7	138.3	-0.3%	185.0	185.5	0.3%
<b>Net profit to shareholders</b>	<b>71.0</b>	<b>72.7</b>	<b>2.3%</b>	<b>101.9</b>	<b>101.6</b>	<b>-0.3%</b>	<b>136.0</b>	<b>136.4</b>	<b>0.3%</b>
<b>EPS</b>	<b>0.5</b>	<b>0.5</b>	<b>2.3%</b>	<b>0.7</b>	<b>0.7</b>	<b>-0.3%</b>	<b>0.9</b>	<b>0.9</b>	<b>0.3%</b>
<b>Healthcare Services</b>									
<b>Sales</b>	<b>1,669.3</b>	<b>1,654.4</b>	<b>-0.9%</b>	<b>1,907.7</b>	<b>1,890.6</b>	<b>-0.9%</b>	<b>2,193.8</b>	<b>2,174.2</b>	<b>-0.9%</b>
Organic growth	15.2%	14.0%	-1.2pp.	15.0%	15.0%	0.0pp.	15.0%	15.0%	0.0pp.
<b>EBITDA</b>	<b>287.5</b>	<b>287.0</b>	<b>-0.2%</b>	<b>329.1</b>	<b>328.0</b>	<b>-0.3%</b>	<b>374.6</b>	<b>376.6</b>	<b>0.5%</b>
EBITDA margin	17.2%	17.3%	0.1pp.	17.2%	17.3%	0.1pp.	17.1%	17.3%	0.2pp.
EBITDAaL	194.0	192.3	-0.9%	226.1	225.0	-0.5%	261.1	263.1	0.8%
EBITDAaL margin	11.6%	11.6%	0.0pp.	11.9%	11.9%	0.1pp.	11.9%	12.1%	0.2pp.
<b>Diagnostic Services</b>									
<b>Sales</b>	<b>769.7</b>	<b>764.0</b>	<b>-0.7%</b>	<b>889.4</b>	<b>875.3</b>	<b>-1.6%</b>	<b>1,013.9</b>	<b>989.1</b>	<b>-2.4%</b>
Organic growth	12.4%	11.8%	-0.7pp.	14.0%	13.0%	-1.0pp.	14.0%	13.0%	-1.0pp.
<b>EBITDA</b>	<b>136.0</b>	<b>138.1</b>	<b>1.6%</b>	<b>158.6</b>	<b>159.3</b>	<b>0.4%</b>	<b>185.5</b>	<b>183.9</b>	<b>-0.8%</b>
EBITDA margin	17.7%	18.1%	0.4pp.	17.8%	18.2%	0.4pp.	18.3%	18.6%	0.3pp.
EBITDAaL	105.3	106.9	1.6%	123.6	124.3	0.5%	143.0	141.4	-1.1%
EBITDAaL margin	13.7%	14.0%	0.3pp.	13.9%	14.2%	0.3pp.	14.1%	14.3%	0.2pp.

Source: ABG Sundal Collier, Company data

## Quarterly P&L forecast

(EURm)	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25e	2024	2025e
<b>Sales</b>	<b>498.8</b>	<b>509.4</b>	<b>527.8</b>	<b>555.8</b>	<b>578.1</b>	<b>596.7</b>	<b>591.6</b>	<b>625.8</b>	<b>2,091.8</b>	<b>2,392.2</b>
Growth	19.0%	19.9%	19.8%	20.3%	15.9%	17.1%	12.1%	12.6%	19.8%	14.4%
Organic growth	14.2%	16.5%	17.4%	18.6%	14.1%	13.9%	12.4%	13.2%	16.7%	13.4%
Medical provision costs	-394.2	-399.5	-414.7	-435.1	-445.4	-454.6	-452.8	-492.0	-1,643.5	-1,844.8
<b>Gross profit</b>	<b>104.6</b>	<b>109.9</b>	<b>113.1</b>	<b>120.7</b>	<b>132.7</b>	<b>142.1</b>	<b>138.8</b>	<b>133.8</b>	<b>448.3</b>	<b>547.4</b>
Gross margin	21.0%	21.6%	21.4%	21.7%	23.0%	23.8%	23.5%	21.4%	21.4%	22.9%
Distribution, selling and marketing costs	-23.2	-23.3	-24.8	-26.5	-27.0	-27.2	-26.2	-28.0	-97.8	-108.4
Administrative costs	-62.4	-65.3	-81.6	-70.9	-69.7	-73.2	-69.8	-69.7	-280.2	-282.4
Other income and costs	0.2	-0.1	0.2	0.1	0.2	1.6	-0.7	0.0	0.4	1.1
<b>EBITDA</b>	<b>67.2</b>	<b>70.6</b>	<b>73.9</b>	<b>73.2</b>	<b>86.5</b>	<b>96.2</b>	<b>98.2</b>	<b>91.8</b>	<b>284.9</b>	<b>372.7</b>
EBITDA margin	13.5%	13.9%	14.0%	13.2%	15.0%	16.1%	16.6%	14.7%	13.6%	15.6%
Items affecting comparability	-2.9	-3.8	-3.4	-5.0	-4.1	-4.7	-3.8	-3.0	-15.1	-15.6
<b>Adj. EBITDA</b>	<b>70.1</b>	<b>74.4</b>	<b>77.3</b>	<b>78.2</b>	<b>90.6</b>	<b>100.9</b>	<b>102.0</b>	<b>94.8</b>	<b>300.0</b>	<b>388.3</b>
Adj. EBITDA margin	14.1%	14.6%	14.6%	14.1%	15.7%	16.9%	17.2%	15.1%	14.3%	16.2%
Depreciation	-48.2	-49.3	-67.2	-49.9	-50.5	-54.5	-55.4	-55.7	-214.6	-216.1
Whereof IFRS 16 leasing depreciation	-20.2	-20.7	-21.6	-21.6	-22.5	-23.9	-24.8	-22.5	-84.1	-93.7
Whereof interest on lease	-6.1	-6.0	-6.2	-6.3	-6.4	-6.6	-7.2	-7.6	-7.2	-7.6
EBITDAaL	40.6	43.3	45.1	44.0	56.3	64.5	65.3	60.3	173.0	246.4
EBITDAaL margin	8.1%	8.5%	8.5%	7.9%	9.7%	10.8%	11.0%	9.6%	8.3%	10.3%
<b>Adj. EBITDAaL</b>	<b>43.5</b>	<b>47.1</b>	<b>48.5</b>	<b>49.0</b>	<b>60.4</b>	<b>69.2</b>	<b>69.1</b>	<b>63.3</b>	<b>188.1</b>	<b>262.0</b>
Adj. EBITDAaL margin	8.7%	9.2%	9.2%	8.8%	10.4%	11.6%	11.7%	10.1%	9.0%	11.0%
EBITA	23.8	26.2	27.6	27.1	39.2	45.7	47.2	49.2	104.7	181.3
EBITA margin	4.8%	5.1%	5.2%	4.9%	6.8%	7.7%	8.0%	7.9%	5.0%	7.6%
Amortisation	-4.8	-4.9	-20.9	-3.8	-3.2	-4.0	-4.4	-5.0	-34.4	-16.6
<b>EBIT</b>	<b>19.0</b>	<b>21.3</b>	<b>6.7</b>	<b>23.3</b>	<b>36.0</b>	<b>41.7</b>	<b>42.8</b>	<b>36.1</b>	<b>70.3</b>	<b>156.6</b>
EBIT margin	3.8%	4.2%	1.3%	4.2%	6.2%	7.0%	7.2%	5.8%	3.4%	6.5%
Net financials	-10.5	-13.1	-14.0	-13.0	-10.1	-18.5	-16.3	-17.0	-50.6	-61.9
<b>Pretax profit</b>	<b>8.7</b>	<b>8.1</b>	<b>-7.1</b>	<b>10.4</b>	<b>26.1</b>	<b>25.0</b>	<b>25.8</b>	<b>19.1</b>	<b>20.1</b>	<b>96.0</b>
Tax	-2.2	-2.2	1.9	-3.0	-7.3	-7.0	-7.2	-5.2	-5.5	-26.7
<b>Net profit</b>	<b>6.5</b>	<b>5.9</b>	<b>-5.2</b>	<b>7.4</b>	<b>18.8</b>	<b>18.0</b>	<b>18.6</b>	<b>14.0</b>	<b>14.6</b>	<b>69.4</b>
Minority	0.3	-0.4	-0.8	-1.2	-1.3	-1.1	-0.9	0.0	-2.1	-3.3
<b>Net profit to shareholders</b>	<b>6.2</b>	<b>6.3</b>	<b>-4.4</b>	<b>8.6</b>	<b>20.1</b>	<b>19.1</b>	<b>19.5</b>	<b>14.0</b>	<b>16.7</b>	<b>72.7</b>
<b>EPS</b>	<b>0.041</b>	<b>0.042</b>	<b>-0.030</b>	<b>0.058</b>	<b>0.133</b>	<b>0.127</b>	<b>0.129</b>	<b>0.092</b>	<b>0.111</b>	<b>0.481</b>

Segment breakdown	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25e	2024	2025e
<b>Healthcare Services</b>	<b>341.8</b>	<b>352.6</b>	<b>370.9</b>	<b>393.4</b>	<b>402.6</b>	<b>414.3</b>	<b>406.5</b>	<b>431.0</b>	<b>1,458.7</b>	<b>1,654.4</b>
Total growth	24%	21%	22%	21%	18%	17%	10%	10%	22%	13%
Organic growth	17%	16%	18%	19%	15%	16%	12%	13%	18%	14%
<b>EBITDA</b>	<b>46</b>	<b>55</b>	<b>58</b>	<b>59</b>	<b>63</b>	<b>77</b>	<b>75</b>	<b>72</b>	<b>217</b>	<b>287</b>
EBITDA margin	13.5%	15.5%	15.5%	15.0%	15.6%	18.6%	18.5%	16.7%	14.9%	17.3%
<b>EBITDAaL</b>	<b>26.1</b>	<b>34.2</b>	<b>36.1</b>	<b>37.1</b>	<b>40.0</b>	<b>53.5</b>	<b>50.5</b>	<b>48.3</b>	<b>133.5</b>	<b>192.3</b>
EBITDAaL margin	7.6%	9.7%	9.7%	9.4%	9.9%	12.9%	12.4%	11.2%	9.2%	11.6%
Intersegment elimination to sales	-0.3	-0.4	-0.4	-1.1	-0.5	-0.5	-0.5	-0.5	-2.2	-2.0
<b>Diagnostic Services</b>	<b>163.1</b>	<b>162.9</b>	<b>162.8</b>	<b>169.2</b>	<b>182.2</b>	<b>189.0</b>	<b>191.7</b>	<b>201.1</b>	<b>658.0</b>	<b>764.0</b>
Total growth	8%	18%	16%	18%	12%	16%	18%	19%	15%	16%
Organic growth	8%	16%	15%	17%	12%	10%	12%	13%	14%	12%
<b>EBITDA</b>	<b>30.2</b>	<b>26.4</b>	<b>26.9</b>	<b>27.2</b>	<b>35.9</b>	<b>33.5</b>	<b>35.8</b>	<b>32.9</b>	<b>110.7</b>	<b>138.1</b>
EBITDA margin	18.5%	16.2%	16.5%	16.1%	19.7%	17.7%	18.7%	16.4%	16.8%	18.1%
<b>EBITDAaL</b>	<b>23.6</b>	<b>19.6</b>	<b>19.5</b>	<b>20.0</b>	<b>28.7</b>	<b>25.6</b>	<b>27.5</b>	<b>25.1</b>	<b>82.7</b>	<b>106.9</b>
EBITDAaL margin	14.5%	12.0%	12.0%	11.8%	15.8%	13.5%	14.3%	12.5%	12.6%	14.0%
Intersegment elimination to sales	-5.9	-5.7	-5.6	-5.8	-6.3	-6.2	-6.1	-5.9	-23.0	-24.5
Group sales elimination	0.1	0.0	0.1	0.1	0.1	-0.1	-0.3	0.1	0.3	-0.2
Eliminations to EBITDA	-9.0	-10.4	-10.5	-13.0	-12.3	-14.5	-12.6	-13.0	-42.9	-52.4
Eliminations to EBITDAaL	-9.1	-10.5	-10.5	-13.1	-12.4	-14.6	-12.7	-13.1	-43.2	-52.8

Source: ABG Sundal Collier, Company data

## Annual P&L forecast

(EURm)	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
<b>Sales</b>	<b>844.4</b>	<b>997.8</b>	<b>1,377.4</b>	<b>1,510.2</b>	<b>1,746.4</b>	<b>2,091.8</b>	<b>2,392.2</b>	<b>2,737.9</b>	<b>3,135.3</b>
Growth	25.7%	18.2%	38.0%	9.6%	15.6%	19.8%	14.4%	14.5%	14.5%
Organic growth	14.8%	11.3%	38.1%	1.9%	11.6%	16.7%	13.4%	14.5%	14.5%
Medical provision costs	-637.6	-734.3	-982.4	-1,174.6	-1,387.0	-1,643.5	-1,844.8	-2,110.0	-2,420.0
<b>Gross profit</b>	<b>206.8</b>	<b>263.5</b>	<b>395.0</b>	<b>335.6</b>	<b>359.4</b>	<b>448.3</b>	<b>547.4</b>	<b>627.9</b>	<b>715.3</b>
Gross margin	24.5%	26.4%	28.7%	22.2%	20.6%	21.4%	22.9%	22.9%	22.8%
Distribution, selling and marketing costs	-45.0	-43.3	-58.1	-66.5	-77.9	-97.8	-108.4	-117.0	-130.0
Administrative costs	-115.3	-158.9	-177.5	-213.6	-220.1	-280.2	-282.4	-310.6	-337.8
Other income and costs	1.0	1.5	0.7	-3.2	8.0	0.4	1.1	0.0	0.0
<b>EBITDA</b>	<b>120.7</b>	<b>157.5</b>	<b>270.4</b>	<b>217.4</b>	<b>243.8</b>	<b>284.9</b>	<b>372.7</b>	<b>438.3</b>	<b>510.5</b>
EBITDA margin	14.3%	15.8%	19.6%	14.4%	14.0%	13.6%	15.6%	16.0%	16.3%
Items affecting comparability	-4.3	-6.6	-10.1	-16.8	-10.1	-15.1	-15.6	-12.0	-12.0
<b>Adj. EBITDA</b>	<b>125.0</b>	<b>164.1</b>	<b>280.5</b>	<b>234.2</b>	<b>253.9</b>	<b>300.0</b>	<b>388.3</b>	<b>450.3</b>	<b>522.5</b>
Adj. EBITDA margin	14.8%	16.4%	20.4%	15.5%	14.5%	14.3%	16.2%	16.4%	16.7%
Depreciation	-74.2	-96.2	-111.0	-161.9	-182.4	-214.6	-216.1	-238.0	-263.0
Whereof IFRS 16 leasing depreciation	-32.9	-38.8	-45.6	-64.1	-74.3	-84.1	-93.7	-86.0	-87.0
Whereof interest on lease	-5.4	-5.8	-6.1	-6.1	-6.0	-6.2	-6.3	-6.4	-6.6
EBITDAaL	80.6	108.5	210.8	131.2	144.9	173.0	246.4	299.9	354.1
EBITDAaL margin	9.5%	10.9%	15.3%	8.7%	8.3%	8.3%	10.3%	11.0%	11.3%
<b>Adj. EBITDAaL</b>	<b>84.9</b>	<b>115.1</b>	<b>220.9</b>	<b>148.0</b>	<b>155.0</b>	<b>188.1</b>	<b>262.0</b>	<b>311.9</b>	<b>366.1</b>
Adj. EBITDAaL margin	10.1%	11.5%	16.0%	9.8%	8.9%	9.0%	11.0%	11.4%	11.7%
EBITA	53.7	76.9	171.2	81.2	82.6	104.7	181.3	261.3	309.5
EBITA margin	6.4%	7.7%	12.4%	5.4%	4.7%	5.0%	7.6%	9.5%	9.9%
Amortisation	-7.2	-15.6	-11.8	-25.7	-21.2	-34.4	-16.6	-30.0	-30.0
<b>EBIT</b>	<b>46.5</b>	<b>61.3</b>	<b>159.4</b>	<b>55.5</b>	<b>61.4</b>	<b>70.3</b>	<b>156.6</b>	<b>200.3</b>	<b>247.5</b>
EBIT margin	5.5%	6.1%	11.6%	3.7%	3.5%	3.4%	6.5%	7.3%	7.9%
Net financials	-12.3	-25.6	-17.3	-32.7	-45.9	-50.6	-61.9	-62.0	-62.0
<b>Pretax profit</b>	<b>33.3</b>	<b>37.3</b>	<b>143.8</b>	<b>19.8</b>	<b>23.6</b>	<b>20.1</b>	<b>96.0</b>	<b>138.3</b>	<b>185.5</b>
Tax	-8.6	-10.0	-37.2	-5.8	-5.2	-5.5	-26.7	-36.6	-49.2
<b>Net profit</b>	<b>24.7</b>	<b>27.3</b>	<b>106.6</b>	<b>14.0</b>	<b>18.4</b>	<b>14.6</b>	<b>69.4</b>	<b>101.6</b>	<b>136.4</b>
Minority	2.2	1.5	4.8	1.9	0.8	-2.1	-3.3	0.0	0.0
<b>Net profit to shareholders</b>	<b>22.5</b>	<b>25.8</b>	<b>101.8</b>	<b>12.1</b>	<b>17.6</b>	<b>16.7</b>	<b>72.7</b>	<b>101.6</b>	<b>136.4</b>
<b>EPS</b>	<b>0.168</b>	<b>0.182</b>	<b>0.686</b>	<b>0.079</b>	<b>0.118</b>	<b>0.111</b>	<b>0.481</b>	<b>0.673</b>	<b>0.903</b>

Segment breakdown	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
<b>Healthcare Services</b>	<b>449.3</b>	<b>539.7</b>	<b>711.6</b>	<b>917.1</b>	<b>1,197.7</b>	<b>1,458.7</b>	<b>1,654.4</b>	<b>1,890.6</b>	<b>2,174.2</b>
Total growth	30%	20%	32%	29%	31%	22%	13%	14%	15%
Organic growth	16%	5%	31%	16%	21%	18%	14%	15%	15%
<b>EBITDA</b>	<b>61</b>	<b>84</b>	<b>111</b>	<b>126</b>	<b>172</b>	<b>217</b>	<b>287</b>	<b>328</b>	<b>377</b>
EBITDA margin	13.6%	15.6%	15.6%	13.7%	14.3%	14.9%	17.3%	17.3%	17.3%
<b>EBITDAaL</b>	<b>41.0</b>	<b>57.5</b>	<b>74.0</b>	<b>65.5</b>	<b>98.6</b>	<b>133.5</b>	<b>192.3</b>	<b>225.0</b>	<b>263.1</b>
EBITDAaL margin	9.1%	10.7%	10.4%	7.1%	8.2%	9.2%	11.6%	11.9%	12.1%
Intersegment elimination to sales	-0.7	-1.6	-1.1	-1.1	-1.4	-2.2	-2.0	-3.0	-3.0
<b>Diagnostic Services</b>	<b>408.7</b>	<b>473.4</b>	<b>686.8</b>	<b>612.5</b>	<b>571.2</b>	<b>658.0</b>	<b>764.0</b>	<b>875.3</b>	<b>989.1</b>
Total growth	21%	16%	45%	-11%	-7%	15%	16%	15%	13%
Organic growth	14%	18%	46%	-13%	-2%	14%	12%	13%	13%
<b>EBITDA</b>	<b>75.7</b>	<b>89.8</b>	<b>179.7</b>	<b>118.7</b>	<b>88.1</b>	<b>110.7</b>	<b>138.1</b>	<b>159.3</b>	<b>183.9</b>
EBITDA margin	18.5%	19.0%	26.2%	19.4%	15.4%	16.8%	18.1%	18.2%	18.6%
<b>EBITDAaL</b>	<b>56.0</b>	<b>67.8</b>	<b>157.1</b>	<b>92.9</b>	<b>62.7</b>	<b>82.7</b>	<b>106.9</b>	<b>124.3</b>	<b>141.4</b>
EBITDAaL margin	13.7%	14.3%	22.9%	15.2%	11.0%	12.6%	14.0%	14.2%	14.3%
Intersegment elimination to sales	-13.2	-14.1	-20.2	-18.5	-21.3	-23.0	-24.5	-25.0	-25.0
Group sales elimination	0.3	0.4	0.3	0.2	0.2	0.3	-0.2	0.0	0.0
Eliminations to EBITDA	-16.0	-16.4	-20.0	-27.2	-16.1	-42.9	-52.4	-49.0	-50.0
Eliminations to EBITDAaL	-16.4	-16.8	-20.3	-27.5	-16.4	-43.2	-52.8	-49.4	-50.4


Source: ABG Sundal Collier, Company data

# Valuation

**We reiterate our fair value range of SEK 220-300, which corresponds to a '25e EV/EBITDA of 12x-15x. It is constructed through modelling based on two peer groups that we consider comparable with Medicover, as well as a DCF.**

To value Medicover, we have compiled two peer groups that we consider comparable with Medicover: one with healthcare providers in developed countries and one with healthcare providers in developing countries. To account for differences in terms of expected sales growth, earnings growth, margin profile, size and risk, we apply a premium to the developed country multiples and a discount to the developing country multiples. We believe this range is the best way to capture the profile of the company, as it reflects a mix of both worlds, similar to Medicover. We also include a three-stage DCF model in the valuation. Using this approach, we find a fair value range of SEK 220-300 per share, which corresponds to a '25e EV/EBITDA of 12x-15x.

## Valuation summary



Source: ABG Sundal Collier, Company data, FactSet

## Peer group overview


Peers - operating and valuation metrics											
	Market Cap (SEK)	Sales CAGR '24-'26e	EBITDA CAGR '24-'26e	Avg. EBITDA margin '24-'26e	Avg. ROCE '24-'26e	EV/ EBITDA 2025e	EV/ EBITDA 2026e	EV/ EBITA 2025e	EV/ EBITA 2026e	P/E 2025e	P/E 2026e
<b>Healthcare, developed countries</b>											
Ramsay Healthcare	44,139	6%	4%	12%	9%	6.4x	6.0x	13.7x	12.0x	23.7x	20.6x
Fresenius SE & Co.	299,977	5%	9%	17%	8%	10.2x	9.1x	14.1x	12.5x	14.3x	12.8x
Sonic Healthcare	63,476	9%	11%	18%	8%	7.4x	6.8x	12.6x	11.5x	18.2x	16.1x
<b>Median</b>	<b>135,864</b>	<b>7%</b>	<b>8%</b>	<b>16%</b>	<b>8%</b>	<b>8.0x</b>	<b>7.3x</b>	<b>13.5x</b>	<b>12.0x</b>	<b>18.7x</b>	<b>16.5x</b>
<b>Healthcare, developing countries</b>											
Apollo Hospitals	121,090	18%	24%	14%	20%	32.4x	25.9x	39.5x	30.0x	63.2x	48.2x
Max Healthcare Institute	119,203	24%	25%	26%	16%	42.0x	33.7x	51.1x	40.6x	65.9x	51.3x
Fortis Healthcare	82,888	17%	27%	22%	14%	39.7x	31.7x	49.5x	37.6x	74.1x	56.0x
<b>Median</b>	<b>107,727</b>	<b>19%</b>	<b>25%</b>	<b>21%</b>	<b>17%</b>	<b>38.0x</b>	<b>30.4x</b>	<b>46.7x</b>	<b>36.0x</b>	<b>67.7x</b>	<b>51.8x</b>
<b>Medicover</b>	<b>35,933</b>	<b>14%</b>	<b>24%</b>	<b>15%</b>	<b>10%</b>	<b>12.4x</b>	<b>10.4x</b>	<b>25.4x</b>	<b>17.5x</b>	<b>44.9x</b>	<b>32.1x</b>
<b>Difference vs. developed</b>		<b>8pp</b>	<b>16pp</b>	<b>-1pp</b>	<b>2pp</b>	<b>54%</b>	<b>43%</b>	<b>89%</b>	<b>46%</b>	<b>140%</b>	<b>95%</b>
<b>Difference vs. developing</b>		<b>-5pp</b>	<b>-1pp</b>	<b>-6pp</b>	<b>-7pp</b>	<b>-67%</b>	<b>-66%</b>	<b>-46%</b>	<b>-51%</b>	<b>-34%</b>	<b>-38%</b>

Source: ABG Sundal Collier, Company data, Factset

### Regression analysis


Our regression on '25e EV/CE multiples (enterprise value divided by capital employed, a proxy for price/book) against the return on capital employed for '26e, and '25e EV/EBITDA multiples against the expected growth in EBITDA for '26e, suggests that Medicover is trading ~37% below what the regression would otherwise suggest.

#### '25e EV/CE vs. '26e ROCE



Source: ABG Sundal Collier, Company data, Factset

#### '25e EV/EBITDA vs. '26e EBITDA growth




Source: ABG Sundal Collier, Company data

### Historical valuation multiples


For reference, we also look at historical valuation multiples, based on FactSet consensus. Historical data on NTM multiples for Medicover show that it is currently trading ~20% below its historical average on NTM EV/EBITDA and EV/EBITA.

#### Medicover NTM EV/EBITDA



Source: ABG Sundal Collier, FactSet

#### Medicover NTM EV/EBITA



Source: ABG Sundal Collier, FactSet

## DCF


We use a three-stage DCF with a WACC of 8.5%. The first stage in our DCF model is based on our detailed forecast for Medicover until 2028e. The second stage in the model is a fading period to 2039e, in which sales growth is assumed to gradually decline to 5.0% and the EBITDA margin is assumed to decline to 13% from an expected level of 15.6% in 2025e. In the third phase of the DCF model, the terminal period, we assume a future free cash flow growth rate of 3.0%.

### Overview of DCF model assumptions

Weighted Cost of Capital - WACC		Cash flow assumptions				DCF value summary	
Risk free yield	3.0%	Forecast period	25e	26e	27e	Present value FCF in stage 1	253
Market risk premium	5.0%	Sales growth	14.4%	14.5%	14.5%	Present value FCF in stage 2	2,051
Equity beta	1.00	EBITDA margin	15.6%	16.0%	16.3%	Present value FCF in TP	2,609
Extra risk factor	2.0%					Total enterprise value	4,912
Company specific risk premium	7.0%	Adaption period - Stage 2 ->			2039		
Cost of equity (Re)	10.0%	Sales growth end stage 2			5.0%	Market value of debt	1,347
		EBITDA margin end stage 2			13.0%	Dividend	-23
EBITA tax rate	25%	Depreciation/sales			-6.0%	Value of shareholders equity	3,543
Cost of debt after tax (Rd)	4.9%	CAPEX/sales end stage 2			6.0%	Time adjustment factor	1.08
Capital weights and WACC						Number of shares	151.0
Debt	30%	Terminal value year			2040		
Equity	70%	FCF growth TP			3.0%		
Implied net debt/equity	43%	EBIT margin TP			7.0%		
WACC	8.5%	CAPEX/sales TP			6.0%		

Source: ABG Sundal Collier

### Sales, sales growth and EBITDA margin




Source: ABG Sundal Collier

### Sensitivity analysis DCF model

		Sales growth end stage 2				
		3.0%	4.0%	5.0%	6.0%	7.0%
EBITDA margin end stage 2	11%	169	176	183	191	199
	12%	212	222	232	242	253
	13%	256	268	280	293	307
	14%	299	314	329	344	361
	15%	343	359	377	395	415

Source: ABG Sundal Collier

### FCF and FCF margin



Source: ABG Sundal Collier

### Sensitivity analysis DCF model

		WACC				
		9.5%	9.0%	8.5%	8.0%	7.5%
FCF growth TP	2.0%	193	219	248	283	324
	2.5%	202	230	263	301	348
	3.0%	213	244	280	324	377
	3.5%	226	260	301	351	413
	4.0%	241	280	326	385	460

Source: ABG Sundal Collier



Income Statement (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	672	844	998	1,377	1,510	1,746	2,092	2,392	2,738	3,135
COGS	-511	-638	-734	-982	-1,175	-1,387	-1,644	-1,845	-2,110	-2,420
Gross profit	161	207	264	395	336	359	448	547	628	715
Other operating items	-70	-86	-106	-125	-118	-116	-163	-175	-190	-205
<b>EBITDA</b>	<b>91</b>	<b>121</b>	<b>158</b>	<b>270</b>	<b>217</b>	<b>244</b>	<b>285</b>	<b>373</b>	<b>438</b>	<b>511</b>
Depreciation and amortisation	-80	-100	-119	-145	-200	-236	-264	-285	-263	-288
of which leasing depreciation	-27	-33	-39	-46	-64	-74	-84	-94	-86	-87
<b>EBITA</b>	<b>37</b>	<b>54</b>	<b>77</b>	<b>171</b>	<b>81</b>	<b>83</b>	<b>105</b>	<b>173</b>	<b>230</b>	<b>278</b>
EO Items	0	0	0	0	0	0	0	0	0	0
Impairment and PPA amortisation	-3	-7	-16	-12	-26	-21	-34	-17	-30	-30
<b>EBIT</b>	<b>34</b>	<b>47</b>	<b>61</b>	<b>159</b>	<b>56</b>	<b>61</b>	<b>70</b>	<b>157</b>	<b>200</b>	<b>248</b>
Net financial items	-9	-12	-26	-17	-33	-46	-51	-62	-62	-62
<b>Pretax profit</b>	<b>32</b>	<b>33</b>	<b>37</b>	<b>144</b>	<b>20</b>	<b>24</b>	<b>20</b>	<b>96</b>	<b>138</b>	<b>186</b>
Tax	-8	-9	-10	-37	-6	-5	-6	-27	-37	-49
<b>Net profit</b>	<b>24</b>	<b>25</b>	<b>27</b>	<b>107</b>	<b>14</b>	<b>18</b>	<b>15</b>	<b>69</b>	<b>102</b>	<b>136</b>
Minority interest	-2	-2	-2	-5	-2	-1	2	3	0	0
Net profit discontinued	0	0	0	0	0	0	0	0	0	0
<b>Net profit to shareholders</b>	<b>22</b>	<b>23</b>	<b>26</b>	<b>102</b>	<b>12</b>	<b>18</b>	<b>17</b>	<b>73</b>	<b>102</b>	<b>136</b>
EPS	0.17	0.17	0.18	0.69	0.08	0.12	0.11	0.48	0.67	0.90
EPS adj.	0.17	0.17	0.18	0.69	0.08	0.12	0.11	0.48	0.67	0.90
Total extraordinary items after tax	7	1	1	1	-2	6	0	1	0	0
Leasing payments	-27	-33	-39	-46	-64	-74	-84	-94	-86	-87
<i>Tax rate (%)</i>	<i>23.7</i>	<i>25.8</i>	<i>26.8</i>	<i>25.9</i>	<i>29.3</i>	<i>22.0</i>	<i>27.4</i>	<i>27.8</i>	<i>26.5</i>	<i>26.5</i>
<i>Gross margin (%)</i>	<i>23.9</i>	<i>24.5</i>	<i>26.4</i>	<i>28.7</i>	<i>22.2</i>	<i>20.6</i>	<i>21.4</i>	<i>22.9</i>	<i>22.9</i>	<i>22.8</i>
<i>EBITDA margin (%)</i>	<i>13.5</i>	<i>14.3</i>	<i>15.8</i>	<i>19.6</i>	<i>14.4</i>	<i>14.0</i>	<i>13.6</i>	<i>15.6</i>	<i>16.0</i>	<i>16.3</i>
<i>EBITA margin (%)</i>	<i>5.5</i>	<i>6.4</i>	<i>7.7</i>	<i>12.4</i>	<i>5.4</i>	<i>4.7</i>	<i>5.0</i>	<i>7.2</i>	<i>8.4</i>	<i>8.9</i>
<i>EBIT margin (%)</i>	<i>5.0</i>	<i>5.5</i>	<i>6.1</i>	<i>11.6</i>	<i>3.7</i>	<i>3.5</i>	<i>3.4</i>	<i>6.5</i>	<i>7.3</i>	<i>7.9</i>
<i>Pre-tax margin (%)</i>	<i>4.7</i>	<i>3.9</i>	<i>3.7</i>	<i>10.4</i>	<i>1.3</i>	<i>1.4</i>	<i>1.0</i>	<i>4.0</i>	<i>5.1</i>	<i>5.9</i>
<i>Net margin (%)</i>	<i>3.6</i>	<i>2.9</i>	<i>2.7</i>	<i>7.7</i>	<i>0.9</i>	<i>1.1</i>	<i>0.7</i>	<i>2.9</i>	<i>3.7</i>	<i>4.3</i>
<b>Growth Rates y-o-y</b>	-	-	-	-	-	-	-	-	-	-
<i>Sales growth (%)</i>	<i>15.8</i>	<i>25.7</i>	<i>18.2</i>	<i>38.0</i>	<i>9.6</i>	<i>15.6</i>	<i>19.8</i>	<i>14.4</i>	<i>14.5</i>	<i>14.5</i>
<i>EBITDA growth (%)</i>	<i>11.3</i>	<i>33.1</i>	<i>30.5</i>	<i>71.7</i>	<i>-19.6</i>	<i>12.1</i>	<i>16.9</i>	<i>30.8</i>	<i>17.6</i>	<i>16.5</i>
<i>EBITA growth (%)</i>	<i>7.9</i>	<i>45.1</i>	<i>43.2</i>	<i>122.6</i>	<i>-52.6</i>	<i>1.7</i>	<i>26.8</i>	<i>65.4</i>	<i>32.9</i>	<i>20.5</i>
<i>EBIT growth (%)</i>	<i>6.3</i>	<i>38.0</i>	<i>31.8</i>	<i>nm</i>	<i>-65.2</i>	<i>10.6</i>	<i>14.5</i>	<i>nm</i>	<i>27.9</i>	<i>23.6</i>
<i>Net profit growth (%)</i>	<i>23.5</i>	<i>2.1</i>	<i>10.5</i>	<i>290.5</i>	<i>-86.9</i>	<i>31.4</i>	<i>-20.7</i>	<i>375.0</i>	<i>46.5</i>	<i>34.2</i>
<i>EPS growth (%)</i>	<i>1.7</i>	<i>0.9</i>	<i>7.9</i>	<i>nm</i>	<i>-88.2</i>	<i>44.8</i>	<i>-5.4</i>	<i>nm</i>	<i>39.9</i>	<i>34.2</i>
<b>Profitability</b>	-	-	-	-	-	-	-	-	-	-
<i>ROE (%)</i>	<i>7.3</i>	<i>7.1</i>	<i>6.7</i>	<i>21.1</i>	<i>2.4</i>	<i>3.6</i>	<i>3.5</i>	<i>14.7</i>	<i>18.2</i>	<i>21.1</i>
<i>ROE adj. (%)</i>	<i>6.2</i>	<i>9.2</i>	<i>10.5</i>	<i>23.4</i>	<i>8.1</i>	<i>6.7</i>	<i>10.6</i>	<i>17.9</i>	<i>23.5</i>	<i>25.7</i>
<i>ROCE (%)</i>	<i>8.7</i>	<i>6.6</i>	<i>7.6</i>	<i>14.8</i>	<i>3.8</i>	<i>4.7</i>	<i>4.3</i>	<i>8.6</i>	<i>10.0</i>	<i>11.9</i>
<i>ROCE adj. (%)</i>	<i>7.5</i>	<i>7.5</i>	<i>9.3</i>	<i>15.8</i>	<i>5.9</i>	<i>5.5</i>	<i>6.4</i>	<i>9.4</i>	<i>11.6</i>	<i>13.4</i>
<i>ROIC (%)</i>	<i>7.3</i>	<i>6.4</i>	<i>7.4</i>	<i>14.3</i>	<i>4.8</i>	<i>4.5</i>	<i>4.9</i>	<i>7.2</i>	<i>9.0</i>	<i>10.6</i>
<i>ROIC adj. (%)</i>	<i>7.3</i>	<i>6.4</i>	<i>7.4</i>	<i>14.3</i>	<i>4.8</i>	<i>4.5</i>	<i>4.9</i>	<i>7.2</i>	<i>9.0</i>	<i>10.6</i>
<b>Adj. earnings numbers</b>	-	-	-	-	-	-	-	-	-	-
EBITDA adj.	91	121	158	270	217	244	285	373	438	511
<i>EBITDA adj. margin (%)</i>	<i>13.5</i>	<i>14.3</i>	<i>15.8</i>	<i>19.6</i>	<i>14.4</i>	<i>14.0</i>	<i>13.6</i>	<i>15.6</i>	<i>16.0</i>	<i>16.3</i>
EBITDA lease adj.	64	88	119	225	153	170	201	279	352	424
<i>EBITDA lease adj. margin (%)</i>	<i>9.5</i>	<i>10.4</i>	<i>11.9</i>	<i>16.3</i>	<i>10.2</i>	<i>9.7</i>	<i>9.6</i>	<i>11.7</i>	<i>12.9</i>	<i>13.5</i>
EBITA adj.	37	54	77	171	81	83	105	173	230	278
<i>EBITA adj. margin (%)</i>	<i>5.5</i>	<i>6.4</i>	<i>7.7</i>	<i>12.4</i>	<i>5.4</i>	<i>4.7</i>	<i>5.0</i>	<i>7.2</i>	<i>8.4</i>	<i>8.9</i>
EBIT adj.	34	47	61	159	56	61	70	157	200	248
<i>EBIT adj. margin (%)</i>	<i>5.0</i>	<i>5.5</i>	<i>6.1</i>	<i>11.6</i>	<i>3.7</i>	<i>3.5</i>	<i>3.4</i>	<i>6.5</i>	<i>7.3</i>	<i>7.9</i>
Pretax profit Adj.	26	40	51	155	49	37	54	112	168	216
Net profit Adj.	21	31	42	118	42	33	49	85	132	166
Net profit to shareholders adj.	19	29	40	113	40	33	51	88	132	166
<i>Net adj. margin (%)</i>	<i>3.1</i>	<i>3.7</i>	<i>4.2</i>	<i>8.6</i>	<i>2.8</i>	<i>1.9</i>	<i>2.3</i>	<i>3.6</i>	<i>4.8</i>	<i>5.3</i>

Source: ABG Sundal Collier, Company Data

Cash Flow (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	91	121	158	270	217	244	285	373	438	511
Net financial items	-9	-12	-26	-17	-33	-46	-51	-62	-62	-62
Paid tax	-8	-9	-10	-37	-6	-5	-6	-27	-37	-49
Non-cash items	30	-22	13	18	-15	28	42	48	0	0
Cash flow before change in WC	105	78	135	234	164	221	271	332	340	399
Change in working capital	-30	9	21	-17	6	-16	-8	-16	-7	-12

Cash Flow (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
<b>Operating cash flow</b>	<b>74</b>	<b>87</b>	<b>156</b>	<b>217</b>	<b>170</b>	<b>205</b>	<b>262</b>	<b>316</b>	<b>333</b>	<b>387</b>
Capex tangible fixed assets	-20	-31	-36	-50	-69	-55	-60	-74	-78	-88
Capex intangible fixed assets	-20	-31	-36	-50	-69	-55	-60	-74	-78	-88
Acquisitions and Disposals	-74	-83	-14	-88	-229	-6	-18	-172	0	0
<b>Free cash flow</b>	<b>-41</b>	<b>-58</b>	<b>71</b>	<b>29</b>	<b>-197</b>	<b>90</b>	<b>124</b>	<b>-3</b>	<b>177</b>	<b>212</b>
Dividend paid	-2	-2	-1	-15	-23	-22	-21	-23	-27	-35
Share issues and buybacks	0	-3	141	-2	-8	-5	-83	-8	0	0
Leasing liability amortisation	-25	-30	-31	-39	-51	-66	-74	-86	-86	-87
Other non-cash items	-120	-165	-42	-214	-140	-61	-124	-47	-31	-32
Balance Sheet (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Goodwill	150	293	289	372	496	517	524	651	651	651
Other intangible assets	51	75	65	75	126	122	133	171	219	277
Tangible fixed assets	164	253	258	319	445	464	492	496	483	457
Right-of-use asset	117	166	180	327	396	412	484	501	501	501
Total other fixed assets	57	17	30	39	34	45	58	68	68	68
Fixed assets	540	804	822	1,133	1,497	1,560	1,692	1,887	1,922	1,954
Inventories	30	37	53	72	58	59	69	78	85	97
Receivables	92	142	149	202	228	258	295	325	356	408
Other current assets	28	2	0	3	0	5	2	5	5	6
Cash and liquid assets	38	35	87	275	49	60	81	78	101	152
<b>Total assets</b>	<b>728</b>	<b>1,020</b>	<b>1,111</b>	<b>1,684</b>	<b>1,832</b>	<b>1,941</b>	<b>2,138</b>	<b>2,373</b>	<b>2,470</b>	<b>2,616</b>
Shareholders equity	313	317	448	518	475	497	465	522	597	698
Minority	4	42	36	45	36	32	25	13	13	13
<b>Total equity</b>	<b>318</b>	<b>360</b>	<b>484</b>	<b>562</b>	<b>511</b>	<b>528</b>	<b>489</b>	<b>535</b>	<b>610</b>	<b>712</b>
Long-term debt	126	164	153	375	473	406	543	668	628	588
Pension debt	0	0	0	0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0	0
Leasing liability	125	176	200	346	424	439	517	548	579	611
Total other long-term liabilities	58	72	81	122	129	138	102	79	79	79
Short-term debt	5	112	15	43	42	159	179	209	209	209
Accounts payable	78	115	149	182	183	205	249	275	301	345
Other current liabilities	18	21	29	54	69	67	59	58	64	73
<b>Total liabilities and equity</b>	<b>728</b>	<b>1,020</b>	<b>1,111</b>	<b>1,684</b>	<b>1,832</b>	<b>1,941</b>	<b>2,138</b>	<b>2,373</b>	<b>2,470</b>	<b>2,616</b>
Net IB debt	165	409	263	462	873	927	1,141	1,330	1,297	1,239
Net IB debt excl. pension debt	165	409	263	462	873	927	1,141	1,330	1,297	1,239
Net IB debt excl. leasing	40	232	64	116	448	488	624	782	718	628
Capital employed	574	811	851	1,326	1,451	1,532	1,728	1,960	2,026	2,120
Capital invested	483	768	747	1,024	1,383	1,455	1,630	1,865	1,907	1,951
Working capital	54	45	24	41	34	50	58	74	81	93
<b>EV breakdown</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Market cap. diluted (m)	2,904	2,904	3,088	3,231	3,244	3,260	3,270	3,289	3,289	3,289
Net IB debt adj.	218	417	281	489	891	944	1,158	1,347	1,315	1,256
Market value of minority	4	42	36	45	36	32	25	13	13	13
Reversal of shares and participations	0	0	0	0	0	0	0	0	0	0
Reversal of conv. debt assumed equity	-	-	-	-	-	-	-	-	-	-
<b>EV</b>	<b>3,127</b>	<b>3,363</b>	<b>3,404</b>	<b>3,765</b>	<b>4,171</b>	<b>4,235</b>	<b>4,453</b>	<b>4,649</b>	<b>4,617</b>	<b>4,558</b>
Total assets turnover (%)	109.0	96.6	93.7	98.6	85.9	92.6	102.6	106.1	113.1	123.3
Working capital/sales (%)	5.9	5.9	3.4	2.3	2.5	2.4	2.6	2.8	2.8	2.8
<b>Financial risk and debt service</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Net debt/equity (%)	52.0	113.6	54.4	82.2	170.8	175.4	233.2	248.6	212.7	174.1
Net debt / market cap (%)	5.7	14.1	8.5	14.3	26.9	28.4	34.9	40.4	39.4	37.7
Equity ratio (%)	43.6	35.3	43.5	33.4	27.9	27.2	22.9	22.5	24.7	27.2
Net IB debt adj. / equity (%)	68.8	115.8	58.0	87.0	174.4	178.7	236.7	251.8	215.5	176.6
Current ratio	1.87	0.87	1.49	1.98	1.14	0.89	0.92	0.90	0.95	1.06
EBITDA/net interest	10.3	9.8	6.2	15.6	6.6	5.3	5.6	6.0	7.1	8.2
Net IB debt/EBITDA (x)	1.8	3.4	1.7	1.7	4.0	3.8	4.0	3.6	3.0	2.4
Net IB debt/EBITDA lease adj. (x)	1.4	2.7	0.7	0.6	3.0	3.0	3.2	2.9	2.1	1.5
Interest coverage	4.2	4.4	3.0	9.9	2.5	1.8	2.1	2.8	3.7	4.5

Source: ABG Sundal Collier, Company Data

Share Data (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Actual shares outstanding	133	133	142	148	149	150	150	151	151	151
Actual shares outstanding (avg)	133	133	142	148	149	150	150	151	151	151

Share Data (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
All additional shares	0	0	0	0	0	0	0	0	0	0
Issue month	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assumed dil. of shares from conv.	0	0	0	0	0	0	0	0	0	0
As. dil. of shares from conv. (avg)	0	0	0	0	0	0	0	0	0	0
Conv. debt not assumed as equity	0	0	0	0	0	0	0	0	0	0
No. of warrants	0	0	0	0	0	0	0	0	0	0
Market value per warrant	0	0	0	0	0	0	0	0	0	0
Dilution from warrants	0	0	0	0	0	0	0	0	0	0
Issue factor	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Actual dividend per share	0.00	0.00	0.07	0.12	0.12	0.12	0.15	0.18	0.23	0.28
Reported earnings per share	0.17	0.17	0.18	0.69	0.08	0.12	0.11	0.48	0.67	0.90

Source: ABG Sundal Collier, Company Data

Valuation and Ratios (EURm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Shares outstanding adj.	133	133	142	148	149	150	150	151	151	151
Diluted shares adj.	133	133	142	148	149	150	150	151	151	151
EPS	0.17	0.17	0.18	0.69	0.08	0.12	0.11	0.48	0.67	0.90
Dividend per share	0.00	0.00	0.07	0.12	0.12	0.12	0.15	0.18	0.23	0.28
EPS adj.	0.17	0.17	0.18	0.69	0.08	0.12	0.11	0.48	0.67	0.90
BVPS	2.35	2.38	3.16	3.49	3.19	3.32	3.10	3.46	3.95	4.62
BVPS adj.	0.84	-0.38	0.66	0.48	-0.99	-0.95	-1.28	-1.99	-1.81	-1.52
Net IB debt/share	1.64	3.13	1.98	3.30	5.98	6.31	7.72	8.92	8.71	8.32
Share price	238.00	238.00	238.00	238.00	238.00	238.00	238.00	238.00	238.00	238.00
Market cap. (m)	2,904	2,904	3,088	3,231	3,244	3,260	3,270	3,289	3,289	3,289
<b>Valuation</b>	-	-	-	-	-	-	-	-	-	-
P/E (x)	nm	nm	nm	31.7	nm	nm	nm	45.3	32.4	24.1
EV/sales (x)	4.7	4.0	3.4	2.7	2.8	2.4	2.1	1.9	1.7	1.5
EV/EBITDA (x)	34.5	27.9	21.6	13.9	19.2	17.4	15.6	12.5	10.5	8.9
EV/EBITA (x)	84.5	62.6	44.3	22.0	51.4	51.3	42.5	26.8	20.0	16.4
EV/EBIT (x)	92.8	72.3	55.5	23.6	75.2	69.0	63.3	29.7	23.1	18.4
Dividend yield (%)	0.0	0.0	0.3	0.6	0.6	0.6	0.7	0.8	1.1	1.3
FCF yield (%)	-1.4	-2.0	2.3	0.9	-6.1	2.8	3.8	-0.1	5.4	6.4
Le. adj. FCF yld. (%)	-2.2	-3.0	1.3	-0.3	-7.6	0.8	1.5	-2.7	2.8	3.8
P/BVPS (x)	9.28	9.15	6.89	6.24	6.83	6.57	7.04	6.30	5.51	4.71
P/BVPS adj. (x)	17.82	119.52	19.44	22.15	-153.04	-159.01	-55.15	-25.44	-60.55	69.46
P/E adj. (x)	nm	nm	nm	31.7	nm	nm	nm	45.3	32.4	24.1
EV/EBITDA adj. (x)	34.5	27.9	21.6	13.9	19.2	17.4	15.6	12.5	10.5	8.9
EV/EBITA adj. (x)	84.5	62.6	44.3	22.0	51.4	51.3	42.5	26.8	20.0	16.4
EV/EBIT adj. (x)	92.8	72.3	55.5	23.6	75.2	69.0	63.3	29.7	23.1	18.4
EV/CE (x)	5.4	4.1	4.0	2.8	2.9	2.8	2.6	2.4	2.3	2.2
<b>Investment ratios</b>	-	-	-	-	-	-	-	-	-	-
Capex/sales (%)	6.1	7.4	7.2	7.3	9.1	6.2	5.7	6.2	5.7	5.6
Capex/depreciation	0.8	0.9	0.9	1.0	1.0	0.7	0.7	0.8	0.9	0.9
Capex tangibles / tangible fixed assets	12.4	12.4	13.9	15.7	15.5	11.8	12.2	14.8	16.1	19.2
Capex intangibles / definite intangibles	--	--	--	--	--	--	--	--	--	--
Depreciation on intang / def. intang	--	--	--	--	--	--	--	--	--	--
Depreciation on tangibles / tangibles	32.7	26.5	31.3	31.1	30.6	34.7	36.6	38.6	36.6	44.0

Source: ABG Sundal Collier, Company Data

## Analyst Certification

We, ABGSC Healthcare Research, Philip Ekengren and Sten Gustafsson, analyst(s) with ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited (hereinafter collectively referred to as "ABG Sundal Collier"), and the author(s) of this report, certify that notwithstanding the existence of any such potential conflicts of interests referred to below, the views expressed in this report accurately reflect my/our personal view about the companies and securities covered in this report. I/We further certify that I/We has/have not been, nor am/are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

This report is produced by ABG Sundal Collier, which may cover companies either in accordance with legal requirements designed to promote the independence of investment research ("independent research") or as commissioned research. Commissioned research is paid for by the subject company. As such, commissioned research is deemed to constitute an acceptable minor non-monetary benefit (i.e., not investment research) as defined in MiFID II.

## Analyst valuation methods

ABG Sundal Collier analysts may publish valuation ranges for stocks covered under Company Sponsored Research. These valuation ranges rely on various valuation methods. One of the most frequently used methods is the valuation of a company by calculation of that company's discounted cash flow (DCF). Another valuation method is the analysis of a company's return on capital employed relative to its cost of capital. Finally, the analysts may analyse various valuation multiples (e.g. the P/E multiples and the EV/EBITDA multiples) relative to global industry peers. In special cases, particularly for property companies and investment companies, the ratio of price to net asset value is considered. Valuation ranges may be changed when earnings and cash flow forecasts are changed. They may also be changed when the underlying value of a company's assets changes (in the cases of investment companies, property companies or insurance companies) or when factors impacting the required rate of return change.

## Expected updates

ABGSC has no fixed schedule for updating its research reports. Unless expressly stated otherwise, ABGSC expects (but does not undertake) to issue updates when considered necessary by the research department, for example following the publication of new figures or forecasts by a company or in the event of any material news on a company or its industry.

## Important Company Specific Disclosure

The following disclosures relate to the relationship between ABG Sundal Collier and its affiliates and the companies covered by ABG Sundal Collier referred to in this research report.

Unless disclosed in this section, ABG Sundal Collier has no required regulatory disclosures to make in relation to an ownership position for the analyst(s) and members of the analyst's household, ownership by ABG Sundal Collier, ownership in ABG Sundal Collier by the company(ies) to whom the report(s) refer(s) to, market making, managed or co-managed public offerings, compensation for provision of certain services, directorship of the analyst, or a member of the analyst's household, or in relation to any contractual obligations to the issuance of this research report.

ABG Sundal Collier has undertaken a contractual obligation to issue this report and receives predetermined compensation from the company covered in this report.

ABG Sundal Collier is not aware of any other actual, material conflicts of interest of the analyst or ABG Sundal Collier of which the analyst knows or has reason to know at the time of the publication of this report.

Production of report: 11/5/2025 16:29.

All prices are as of market close on 4 November, 2025 unless otherwise noted.

## Disclaimer

This report has been prepared by ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited and any of their directors, officers, representatives and employees (hereinafter collectively referred to as "ABG Sundal Collier"). This report is not a product of any other affiliated or associated companies of any of the above entities.

This report is provided solely for the information and use of professional investors, who are expected to make their own investment decisions without undue reliance on this report. The information contained herein does not apply to, and should not be relied upon by, retail clients. This report is for distribution only under such circumstances as may be permitted by applicable law. Research reports prepared by ABG Sundal Collier are for information purposes only. The recommendation(s) in this report is (are) has/have no regard to specific investment objectives and the financial situation or needs of any specific recipient. ABG Sundal Collier and/or its affiliates accepts no liability whatsoever for any losses arising from any use of this report or its contents. This report is not to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but ABG Sundal Collier and/or its affiliates make no representation as to its accuracy or completeness and it should not be relied upon as such. All opinions and estimates herein

reflect the judgment of ABG Sundal Collier on the date of this report and are subject to change without notice. Past performance is not indicative of future results.

The compensation of our research analysts is determined exclusively by research management and senior management, but not including investment banking management. Compensation is not based on specific investment banking revenues, however, it is determined from the profitability of the ABG Sundal Collier group, which includes earnings from investment banking operations and other business. Investors should assume that ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge and/or ABG Sundal Collier AB is seeking or will seek investment banking or other business relationships with the companies in this report.

The research analyst(s) responsible for the preparation of this report may interact with trading desk and sales personnel and other departments for the purpose of gathering, synthesizing and interpreting market information. From time to time, ABG Sundal Collier and/or its affiliates and any shareholders, directors, officers, or employees thereof may (I) have a position in, or otherwise be interested in, any securities directly or indirectly connected to the subject of this report, or (II) perform investment banking or other services for, or solicit investment banking or other services from, a company mentioned in this report. ABG Sundal Collier and/or its affiliates rely on information barriers to control the flow of information contained in one or more areas of ABG Sundal Collier, into other areas, units, groups or affiliates of ABG Sundal Collier.

Norway: ABG Sundal Collier ASA is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet)

Denmark: ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet) and the Danish Financial Supervisory Authority (Finanstilsynet)

Sweden: ABG Sundal Collier AB is regulated by the Swedish Financial Supervisory Authority (Finansinspektionen)

UK: This report is a communication made, or approved for communication in the UK, by ABG Sundal Collier Limited, authorised and regulated by the Financial Conduct Authority in the conduct of its business.

US: This report is being distributed in the United States (U.S.) in accordance with FINRA Rule 1220 by ABG Sundal Collier Inc., an SEC registered broker-dealer and a FINRA/SIPC member which accepts responsibility for its content and its compliance with FINRA Rule 2241. Research reports distributed in the U.S. are intended solely for "major U.S. institutional investors," and "U.S. institutional investors" as defined under Rule 15a-6 of the Securities Exchange Act of 1934 and any related interpretive guidance and no-action letters issued by the Staff of the U.S. Securities and Exchange Commission ("SEC") collectively ("SEC Rule 15a-6"). Each major U.S. institutional investor and U.S. institutional investor that receives a copy of this research report, by its acceptance of such report, represents that it agrees that it will not distribute this research report to any other person. This communication is only intended for major U.S. institutional investors and U.S. institutional investors. Any person which is not a major U.S. institutional investor, or a U.S. institutional investor as covered by SEC Rule 15a-6 must not rely on this communication. The delivery of this research report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. Any major U.S. institutional investor or U.S. institutional investor receiving this report which wishes to effect transactions in any securities referred to herein should contact ABG Sundal Collier Inc., not its affiliates. Further information on the securities referred to herein may be obtained from ABG Sundal Collier Inc., on request.

Singapore: This report is distributed in Singapore by ABG Sundal Collier Pte. Ltd, which is not licensed under the Financial Advisors Act (Chapter 110 of Singapore). In Singapore, this report may only be distributed to institutional investors as defined in Section 4A(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"), and should not be circulated to any other person in Singapore.

Canada: This report is being distributed by ABG Sundal Collier ASA in Canada pursuant to section 8.25 of National Instrument 31-103 or an equivalent provision and has not been tailored to the needs of any specific investor in Canada. The information contained in this report is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering or an offer to sell the securities described herein, in Canada or any province or territory thereof. No securities commission or similar regulatory authority in Canada has reviewed or considered this report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Under no circumstances is this report to be construed as an offer to sell such securities or as a solicitation of an offer to buy such securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada may only be made in accordance with applicable securities laws and only by a dealer properly registered under such securities laws, or alternatively, pursuant to an applicable dealer registration exemption, in the Canadian jurisdiction in which such offer or sale is made.

This report may not be reproduced, distributed, or published by any recipient for any purpose whatsoever without the prior written express permission of ABG Sundal Collier.

**Additional information available upon request. If reference is made in this report to other companies and ABG Sundal Collier provides research coverage for those companies, details regarding disclosures may be found on our website [www.abgsc.com](http://www.abgsc.com).**

© Copyright 2025 ABG Sundal Collier ASA

**Norway**

Ruseløkkveien 26, 8th floor  
0251 Oslo  
Norway  
Tel: +47 22 01 60 00  
Fax: +47 22 01 60 60

**Denmark**

Forbindelsesvej 12,  
2100 Copenhagen  
Denmark  
Tel: +45 35 46 61 00  
Fax: +45 35 46 61 10

**Sweden**

Regeringsgatan 25, 8th floor  
111 53 Stockholm  
Sweden  
Tel: +46 8 566 286 00  
Fax: +46 8 566 286 01

**United Kingdom**

10 Paternoster Row, 5th floor  
London EC4M 7EJ  
UK  
Tel: +44 20 7905 5600  
Fax: +44 20 7905 5601

**USA**

140 Broadway, Suite 4604  
New York, NY 10005  
USA  
Tel. +1 212 605 3800  
Fax. +1 212 605 3801

**Singapore**

10 Collyer Quay  
Ocean Financial Center  
#40-07, Singapore 049315  
Tel +65 6808 6082

**Germany**

Schillerstrasse 2, 5. OG  
60313 Frankfurt  
Germany  
Tel +49 69 96 86 96 0  
Fax +49 69 96 86 96 99

**Switzerland**

ABG Sundal Collier AG  
Representative Office  
Schwanenplatz 4  
6004 Lucerne  
Switzerland  
Tel +41 79 502 33 39